The Italian Government has agreed with France and Germany to set up a branch of the central division of the Unified Patent Court in Milan.  This has been announced by the Italian ministry of foreign affairs and international cooperation. According to a press release, the agreement will be submitted to the other UP member states…

The concept of plausibility has caused great controversy in European patent law in recent years. It was hoped that the decision of the Enlarged Board of Appeal (EBA) of the EPO in G 2/21 would bring clarity. Since the referral questions by Board 3.3.02 were very clear and seemed to present reasonable alternatives from which…

The industry has serious concerns about the deteriorating patent quality at the European Patent Office. The issue was discussed earlier this month between the EPO and the Industry Patent Quality Charter, an group representing major international corporations, law firms and patent offices. After their meeting, Beat Weibel, chief IP counsel, group senior vice-president at Siemens…

The new and noteworthy decision T 670/20 by Technical Board of Appeal 3.3.07 provides more legal certainty for patentees of formulation patents. The proprietors of pharmaceutical formulation and pharmaceutical use patents do often not have it easy, if and when – as is often the case – they have conducted clinical trials before the priority…

Damocles, so tells us an ancient legend (reported here) was a favorite of President Dionysios II. of Syrakus in Sicily, who lived during the first half of the 4th century BC. His story was succinctly told by none other than Marcus Tullius Cicero in his tusculanae disputationes 5, 61–62. Hoping that Cicero will forgive me,…

An outburst of anger of a president and his re-election, social tensions, industrial actions: for anyone familiar with the world of patents it will be clear that all this refers to the European Patent Office, which drew a lot of attention on the Kluwer Patent Blog last year, even more than the biggest change in…